Joel Ledbetter1, Lance Brannman2, Sally W Wade3, Tara Gonzales2, Amanda M Kong4. 1. Pediatric Pulmonology, Childrens Hospital at Erlanger, Chattanooga, TN, USA. 2. US Medical Affairs, AstraZeneca, Gaithersburg, MD, USA. 3. Wade Outcomes Research and Consulting, Salt Lake City, UT, USA. 4. Life Sciences, IBM Watson Health, Cambridge, MA, USA.
Abstract
Aims: To examine healthcare resource utilization (HRU) and costs within 12 months after hospitalization for respiratory syncytial virus (RSVH) or unspecified bronchiolitis (UBH) in infants.Materials and methods: Infants born July 1, 2009-June 30, 2015 were identified in the MarketScan Medicaid and Commercial databases and were assigned to one of three cohorts: RSVH (with/without UBH), UBH, or comparator (no RSVH or UBH). Each infant was identified as pre-term (5 groups) or term (2 groups) based on weeks gestational age (wGA). Index dates were the first admission dates for RSVH or UBH infants and were randomly assigned to comparator infants based on time from birth to index in the RSVH cohort. HRU, all-cause costs, and incremental cost differences between hospitalized and comparator infants were assessed over 12 months post-index with and without the index hospitalization. Results were propensity score weighted to balance pre-index characteristics across hospitalization cohorts. Results: This study identified 15,872 RSVH infants, 6,081 UBH infants, and 986,087 comparator infants in the Medicaid population and 5,755 RSVH infants, 1,888 UBH infants, and 696,302 comparator infants in the commercial population. HRU in follow-up was greater for RSVH and UBH infants relative to comparator infants in both populations, including hospitalizations (commercial: 7.4%, 11.0%, 1.7%; Medicaid: 12.3%, 15.3%, 3.2%) and emergency department visits (commercial: 33.0%, 33.3%, 17.2%; Medicaid: 65.8%, 68.5%, 51.4%). HRU was highest among RSVH and UBH infants born at <29 wGA. Hospitalized infants had numerically higher follow-up costs than comparator infants, with incremental differences reaching $19,896 among Medicaid UBH infants and $37,417 among commercial RSVH infants.Limitations: RSV/UB may be miscoded in claims data.Conclusions: Infants hospitalized for RSV or UB largely had greater subsequent HRU and costs in the first year after index hospitalization than comparator infants. Absolute and incremental follow-up costs relative to comparator infants were highest among infants <29 wGA.
RCT Entities:
Aims: To examine healthcare resource utilization (HRU) and costs within 12 months after hospitalization for respiratory syncytial virus (RSVH) or unspecifiedbronchiolitis (UBH) in infants.Materials and methods: Infants born July 1, 2009-June 30, 2015 were identified in the MarketScan Medicaid and Commercial databases and were assigned to one of three cohorts: RSVH (with/without UBH), UBH, or comparator (no RSVH or UBH). Each infant was identified as pre-term (5 groups) or term (2 groups) based on weeks gestational age (wGA). Index dates were the first admission dates for RSVH or UBHinfants and were randomly assigned to comparator infants based on time from birth to index in the RSVH cohort. HRU, all-cause costs, and incremental cost differences between hospitalized and comparator infants were assessed over 12 months post-index with and without the index hospitalization. Results were propensity score weighted to balance pre-index characteristics across hospitalization cohorts. Results: This study identified 15,872 RSVHinfants, 6,081 UBHinfants, and 986,087 comparator infants in the Medicaid population and 5,755 RSVHinfants, 1,888 UBHinfants, and 696,302 comparator infants in the commercial population. HRU in follow-up was greater for RSVH and UBHinfants relative to comparator infants in both populations, including hospitalizations (commercial: 7.4%, 11.0%, 1.7%; Medicaid: 12.3%, 15.3%, 3.2%) and emergency department visits (commercial: 33.0%, 33.3%, 17.2%; Medicaid: 65.8%, 68.5%, 51.4%). HRU was highest among RSVH and UBHinfants born at <29 wGA. Hospitalized infants had numerically higher follow-up costs than comparator infants, with incremental differences reaching $19,896 among Medicaid UBHinfants and $37,417 among commercial RSVHinfants.Limitations: RSV/UB may be miscoded in claims data.Conclusions: Infants hospitalized for RSV or UB largely had greater subsequent HRU and costs in the first year after index hospitalization than comparator infants. Absolute and incremental follow-up costs relative to comparator infants were highest among infants <29 wGA.
Authors: Ellen Rafferty; Mike Paulden; Sarah A Buchan; Joan L Robinson; Julie A Bettinger; Manoj Kumar; Lawrence W Svenson; Shannon E MacDonald Journal: Pharmacoeconomics Date: 2022-05-13 Impact factor: 4.558
Authors: Diana M Bowser; Katharine R Rowlands; Dhwani Hariharan; Raíssa M Gervasio; Lauren Buckley; Yara Halasa-Rappel; Elizabeth L Glaser; Christopher B Nelson; Donald S Shepard Journal: J Infect Dis Date: 2022-08-15 Impact factor: 7.759
Authors: Gabriela B Gomez; Christopher B Nelson; Christopher Rizzo; Donald S Shepard; Sandra S Chaves Journal: J Infect Dis Date: 2022-08-15 Impact factor: 7.759
Authors: Mina Suh; Naimisha Movva; Xiaohui Jiang; Heidi Reichert; Lauren C Bylsma; Jon P Fryzek; Christopher B Nelson Journal: J Infect Dis Date: 2022-08-15 Impact factor: 7.759